Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472174 | 0.81 | ALDH1A1 (0.44) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL3258992 | 0.79 | CES2 (0.34) | ALDH1A1TSHRTDP1ESR1 | |
| SCHEMBL9017765 | 0.79 | ALDH1A1 (0.52) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL14119556 | 0.76 | ALDH1A1 (0.34) | ALDH1A1ATMTSHRHPGDLMNA | |
| SCHEMBL3257813 | 0.75 | CES2 (0.32) | ALDH1A1TSHRTDP1ESR1 | |
| SCHEMBL14119554 | 0.75 | ACHE (0.30) | — | |
| SCHEMBL3104104 | 0.74 | ALDH1A1 (0.47) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL7208725 | 0.74 | NAAA (0.47) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL1473948 | 0.74 | ALDH1A1 (0.52) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL16086360 | 0.73 | NAAA (0.50) | ALDH1A1ATMTSHRHCAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915242-B2 | eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915242-B2 | eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915242-B2 | eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-20050182033-A1 | Vitamin D receptor antagonists and their use in treating asthma | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182033-A1 | Vitamin D receptor antagonists and their use in treating asthma | VDR, CYP2R1, CYP24A1 | ALDH1A1 2708/4885ATM 4776/4885TSHR 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.